Company Search
CEO Interview
Drive With Dynacor Video Series
TSX_DNG on 2012-05-17 10:38Dynacor has released a new video series called the "Drive With Dynacor". http://youtu.be/seFbg2CXt6U
NAI Blog
My Top Junior Oil Stock in the Permian Basin “Tight” Oil Play Keith Schaefer on 2012-04-26 07:40:54Part 2: The Permian Basin – Cline Shale Resource Play
Company News - Company Data
Amorfix to collaborate with world leader in prion diagnostic research
Posted 2012-05-01 01:27NAI Editing
Amorfix Life Sciences Ltd. announced today that the Company has established a collaboration with Dr.Amorfix Chief Scientific Officer receives Genome BC Award for Scientific Excellence
Posted 2012-04-17 01:23NAI Editing
announces that its Chief Scientific Officer, Director and Company founder, Dr. Neil Cashman, has been awarded the 2012 Genome BC Award for Scientific Excellence.Amorfix Establishes Proof of Concept of Lead Tumor-specific Antibody for the Treatment of Ovarian Cancer
Posted 2012-04-04 01:26NAI Editing
announces that it has completed a series of studies with its lead anti-PrP antibody that demonstrate specific, dose-related killing of ovarian tumor cells.Amorfix Acquires SOD1 Technology and Provides Update on Financing
Posted 2012-03-12 01:16NAI Editing
announces that it has exercised its option to acquire the SOD1 technology it had licensed from Chief Scientific Officer, Dr. Neil Cashman.Amorfix Appoints Lynda Covello Vice President of Strategic Alliances
Posted 2012-02-23 01:42NAI Editing
, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced the Company has appointed Lynda Covello as Vice President of Strategic AlliancesAmorfix Announces Third Quarter Fiscal 2012 Results
Posted 2012-02-10 01:24NAI Editing
, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the third quarter ended December 31, 2Amorfix Closes First Tranche of Private Placement
Posted 2012-01-18 00:47NAI Editing
announces that it has closed the first tranche of a non-brokered private placement (the Offering) pursuant to which a total of 3,012,532 units (Units) were issued at a price of $0.225 per unit for groAmorfix and JSW Sign LOI for Exclusive Worldwide License of Preclinical Alzheimer's Disease Diagnostic Technology
Posted 2012-01-09 00:43NAI Editing
, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has signed a letter of intent with JSW-Lifesciences GmbH, a contract resAmorfix Announces Private Placement
Posted 2011-12-13 00:21NAI Editing
announced today that it intends to complete, subject to regulatory approval, a non-brokered private placement of between approximately 2,222,222 units (Units) at a price of $0.225 per Unit, for gross Amorfix Will Develop a Diagnostic Test and Complete its ALS Disease Management Product Portfolio
Posted 2011-11-17 01:41NAI Editing
, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that the Company is developing a blood test to be used as a diagnostic tool for
Posted 2012-05-01 01:27
NAI EditingAmorfix Life Sciences Ltd. announced today that the Company has established a collaboration with Dr.Amorfix Chief Scientific Officer receives Genome BC Award for Scientific Excellence
Posted 2012-04-17 01:23
NAI Editingannounces that its Chief Scientific Officer, Director and Company founder, Dr. Neil Cashman, has been awarded the 2012 Genome BC Award for Scientific Excellence.Amorfix Establishes Proof of Concept of Lead Tumor-specific Antibody for the Treatment of Ovarian Cancer
Posted 2012-04-04 01:26
NAI Editingannounces that it has completed a series of studies with its lead anti-PrP antibody that demonstrate specific, dose-related killing of ovarian tumor cells.Amorfix Acquires SOD1 Technology and Provides Update on Financing
Posted 2012-03-12 01:16
NAI Editingannounces that it has exercised its option to acquire the SOD1 technology it had licensed from Chief Scientific Officer, Dr. Neil Cashman.Amorfix Appoints Lynda Covello Vice President of Strategic Alliances
Posted 2012-02-23 01:42
NAI Editing, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced the Company has appointed Lynda Covello as Vice President of Strategic AlliancesAmorfix Announces Third Quarter Fiscal 2012 Results
Posted 2012-02-10 01:24
NAI Editing, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the third quarter ended December 31, 2Amorfix Closes First Tranche of Private Placement
Posted 2012-01-18 00:47
NAI Editingannounces that it has closed the first tranche of a non-brokered private placement (the Offering) pursuant to which a total of 3,012,532 units (Units) were issued at a price of $0.225 per unit for groAmorfix and JSW Sign LOI for Exclusive Worldwide License of Preclinical Alzheimer's Disease Diagnostic Technology
Posted 2012-01-09 00:43
NAI Editing, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has signed a letter of intent with JSW-Lifesciences GmbH, a contract resAmorfix Announces Private Placement
Posted 2011-12-13 00:21
NAI Editingannounced today that it intends to complete, subject to regulatory approval, a non-brokered private placement of between approximately 2,222,222 units (Units) at a price of $0.225 per Unit, for gross Amorfix Will Develop a Diagnostic Test and Complete its ALS Disease Management Product Portfolio
Posted 2011-11-17 01:41
NAI Editing, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that the Company is developing a blood test to be used as a diagnostic tool for